Fulcrum Therapeutics, Inc. 8K

Slate Medicines, Inc. executed a stockholder support agreement securing a key Fulcrum Therapeutics stockholder’s binding support and voting commitments for a planned merger between Slate and Fulcrum.

On or about 2026-08-16, Slate Medicines, Inc. entered into a Parent Stockholder Support Agreement with a specified stockholder of Fulcrum Therapeutics, Inc., under which the stockholder agrees to vote all of its Fulcrum common shares and equity awards in favor of a proposed two-step merger between Slate and Fulcrum (via Fulcrum’s wholly owned merger subsidiaries), against competing or alternative acquisition proposals, to refrain from transferring or encumbering the subject shares except for limited permitted transfers subject to this agreement, to grant Slate an irrevocable proxy to vote the subject shares as required, to waive appraisal and dissenters’ rights, and to comply with non-solicitation and confidentiality obligations, with the agreement automatically terminating upon the earlier of the merger agreement’s termination, the effective time of the merger, or certain adverse amendments to the merger agreement.

Filing Facts

CIK

1680581

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-353278

Alert Tier

8